尿嘧啶替加氟(Tegafur/Uracil) - 药物靶点：TYMS_在研适应症：膀胱癌，头颈部肿瘤，前列腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Compound Tegafur、Orzel、Uftoral

+ [11]

靶点

TYMS

作用方式

抑制剂

作用机制

TYMS抑制剂(胸苷酸合成酶抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [4]

在研适应症

膀胱癌头颈部肿瘤前列腺癌+ [9]

非在研适应症

转移性食管癌III期结肠癌

原研机构

Taiho Pharmaceutical Co., Ltd.

在研机构

Bristol Myers Squibb Co.

Taiho Pharmaceutical Co., Ltd.

非在研机构

Merck AB (Sweden)

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (1983-05-27),

胆管癌乳腺癌结直肠癌+ [5]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C12H13FN4O5

InChIKeyDHMYGZIEILLVNR-UHFFFAOYSA-N

CAS号74578-38-4

关联

96

项与尿嘧啶替加氟相关的临床试验

JPRN-jRCTs031210660

/ Recruiting临床2期IIT

A prospective study on the safety and efficacy of preoperative UFT/UZEL+CPT-11+irradiation combined with FOLFOX or CAPOX for locally advanced lower rectal cancer

开始日期2022-06-14

申办/合作机构-

JPRN-UMIN000046430

/ SuspendedN/AIIT

Multi-institutional study aimed at radical cure with multidisciplinary treatment including preoperative endocrine chemotherapy (LHRH analog, denosumab, apalutamide, tegafur / uracil), robot-assisted total prostatectomy and radiation therapy for prostate cancer with oligometastases of bone - Multi-institutional study aimed at radical cure with multidisciplinary treatment including preoperative endocrine chemotherapy, robot-assisted total prostatectomy and radiation therapy for prostate cancer with oligometastases of bone

开始日期2021-12-01

申办/合作机构-

JPRN-jRCT1051190106

/ CompletedN/AIIT

Safety and efficacy of postoperative adjuvant chemotherapy with L-OHP base regimen followed by UFT plus LV for resectable liver metastases fro m colorectal cancer. (LOFT trial ) - LOFT trial

开始日期2020-02-13

申办/合作机构-

100 项与尿嘧啶替加氟相关的临床结果

登录后查看更多信息

100 项与尿嘧啶替加氟相关的转化医学

登录后查看更多信息

100 项与尿嘧啶替加氟相关的专利（医药）

登录后查看更多信息

2,237

项与尿嘧啶替加氟相关的文献（医药）

2025-04-01·Seminars in Thoracic and Cardiovascular Surgery

Adjuvant Therapy in Stage IB Non-Small Cell Lung Cancer: A Network Meta-Analysis of Tegafur-Uracil and Immune Checkpoint Inhibitors

Review

作者: Yamanashi, Keiji ; Hamaji, Masatsugu ; Takeuchi, Jiro ; Miyata, Ryo ; Hosono, Mitsuharu ; Ozu, Naoki ; Kawaguchi, Takeshi

Recent clinical trials demonstrated that as adjuvant therapy, immune checkpoint inhibitors (ICIs) following intravenous cytotoxic chemotherapy may have a nonsignificant advantage over intravenous cytotoxic chemotherapy only in completely resected stage IB non-small cell lung cancer (NSCLC). Meanwhile, several studies reported that oral tegafur-uracil may have a comparable benefit to intravenous chemotherapy in long-term survival outcomes in these patients. However, there is currently a lack of head-to-head comparison between ICIs following intravenous cytotoxic chemotherapy and tegafur-uracil. Therefore, we designed a network meta-analysis in assessing overall survival (OS) and a composite endpoint of disease free survival (DFS) and recurrence free survival (RFS) as measures of effect. Our results indicated that, limited to stage IB, calculated hazard ratio (HR) was 1.02 (95% confidence interval [CI]: 0.53-1.96) for OS and calculated HR was 0.90 (95% CI: 0.43-1.87) for DFS, while in stage IB to IIIA patients, calculated HR was 0.97 (95% CI: 0.70-1.37) for OS and calculated HR was 0.75 (95% CI: 0.59-0.95) for DFS. In conclusion, tegafur-uracil may offer a comparable benefit to ICIs following chemotherapy in limitation to stage IB NSCLC patients only. Future clinical trials may be designed for stage IB NSCLC, separately from stage II and III.

2025-03-01·EUROPEAN JOURNAL OF CANCER

Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial

Article

作者: Fujiwara, Hiroyuki ; Saito, Motoaki ; Yamamoto, Kouji ; Yamaguchi, Satoshi ; Kurosaki, Akira ; Takano, Hirokuni ; Nagai, Tomonori ; Nishio, Shin ; Fujiwara, Keiichi ; Itagaki, Hiroya ; Suzuki, Yurina ; Takehara, Kazuhiro ; Nakamura, Kazuto ; Kudoh, Akiko ; Kobayashi, Hiroaki ; Yahata, Hideaki ; Hasegawa, Kosei ; Kamio, Masaaki ; Kato, Kazuyoshi ; Nakamoto, Tomoko

AIM:

Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer (LACC), but recurrence rates remain high. This multicenter phase-3 randomized trial (GOTIC-002) evaluated the efficacy of low-dose oral tegafur-uracil (UFT) as maintenance chemotherapy following curative CCRT for LACC.

METHODS:

Between 2010 and 2018, 351 patients with stage Ib2-IVa cervical cancer were enrolled. After achieving complete or partial remission post-CCRT, patients were randomized 1:1 into observation (arm O) or UFT maintenance therapy (arm UFT). UFT doses were 300-400 mg/day based on body surface area for 2 years, disease progression or adverse effects occurred. The primary endpoint was progression-free survival (PFS), with overall survival (OS) and safety as secondary endpoints.

RESULTS:

Patient characteristics were similar between the groups (n = 178 in arm O, n = 173 in arm UFT). During a median follow-up of 3 years, median PFS was not reached in either group. 5-year PFS rates were similar between them (arm O: 61.3 %, arm UFT: 62.0 %, hazard ratio: 0.92, P = .634). 5-year OS rates were also comparable (77.6 % vs 76.1 %, hazard ratio: 1.04, P = .869). Compliance with UFT ranged from 87.8 % to 98.8 %. Although adverse events were more frequent in arm UFT (93.5 % vs 73.9 %, odds ratio: 5.05), most were mild or moderate. Despite its tolerability, UFT did not improve PFS or OS.

CONCLUSIONS:

These findings suggest the need to reconsider maintenance therapy strategies after CCRT for potentially shifting away from cytotoxic chemotherapy towards alternative methods to enhance survival outcomes in patients with LACC.

2025-03-01·Annals of Gastroenterological Surgery

Efficacy of the U‐shaped flap technique in preventing reflux after minimally invasive proximal gastrectomy for proximal gastric and esophagogastric junction cancer

Article

作者: Wada, Hiroshi ; Kanemura, Takashi ; Omori, Takeshi ; Shinno, Naoki ; Miyata, Hiroshi ; Hara, Hisashi ; Yanagimoto, Yoshitomo ; Yasui, Masayoshi ; Ohue, Masayuki ; Masuike, Yasunori

Abstract:

Background:

Preventing gastroesophageal reflux after proximal gastrectomy for proximal gastric and esophagogastric junction cancer remains challenging due to the lack of standardized reconstructive techniques. The double flap technique (DFT) in valvuloplastic esophagogastrostomy prevents reflux esophagitis but is less effective in esophagogastric junction cancer because of negative pressure on the inferior mediastinum. We developed the U‐shaped flap technique (UFT) to enhance the anti‐reflux efficacy.

Methods:

This study analyzed data from patients who underwent minimally invasive proximal gastrectomy for proximal gastric and esophagogastric junction cancer between August 2014 and May 2022, using a prospectively maintained database. We compared DFT and UFT for short‐ and long‐term outcomes, focusing on gastroesophageal reflux, using one‐to‐one propensity score matching to control for patient‐related variables.

Results:

Among 217 eligible patients, 205 (100 in DFT, 105 in UFT) completed a 1‐year follow‐up. After propensity score matching, we selected 42 pairs of patients who underwent DFT and UFT. UFT had significantly shorter operative time (p = 0.044), similar blood loss, and similar morbidity. The UFT group had significantly fewer reflux symptoms (0% vs. 14.3%, p = 0.0011) and endoscopic Los Angeles grade B or higher reflux esophagitis (0% vs. 14.3%, p = 0.0011) than the DFT group. In lower mediastinal reconstructions for esophagogastric junction cancer, UFT showed a reduced incidence of reflux esophagitis.

Conclusion:

Our study indicates that the U‐shaped flap technique (UFT) offered significant advantages in reducing postoperative reflux symptoms and endoscopic esophagitis, in a cohort of patients with proximal gastric and esophagogastric junction cancer.

100 项与尿嘧啶替加氟相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	尿嘧啶替加氟	-	DB09327

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
膀胱癌	日本	Taiho Pharmaceutical Co., Ltd.	1986-08-28
头颈部肿瘤	日本	Taiho Pharmaceutical Co., Ltd.	1986-08-28
前列腺癌	日本	Taiho Pharmaceutical Co., Ltd.	1986-08-28
宫颈癌	日本	Taiho Pharmaceutical Co., Ltd.	1986-08-28
胆管癌	日本	Taiho Pharmaceutical Co., Ltd.	1983-05-27
乳腺癌	日本	Taiho Pharmaceutical Co., Ltd.	1983-05-27
结直肠癌	日本	Taiho Pharmaceutical Co., Ltd.	1983-05-27
胆囊肿瘤	日本	Taiho Pharmaceutical Co., Ltd.	1983-05-27
肝癌	日本	Taiho Pharmaceutical Co., Ltd.	1983-05-27
肺癌	日本	Taiho Pharmaceutical Co., Ltd.	1983-05-27
胰腺癌	日本	Taiho Pharmaceutical Co., Ltd.	1983-05-27
胃癌	日本	Taiho Pharmaceutical Co., Ltd.	1983-05-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
III期结肠癌	临床3期	日本	Taiho Pharmaceutical Co., Ltd.	1996-10-01
转移性食管癌	临床2期	美国	Bristol Myers Squibb Co.	2002-05-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCLC2024 人工标引	N/A	转移性非小细胞肺癌辅助 EGFR mutation-positive	1,812	Tegafur/Uracilur/Uracil	築選遞糧築齋膚網鬱壓(糧築鹹鏇鑰鹹網衊齋齋) = 窪願鑰積鹽糧網鏇衊齋製願壓廠憲廠艱齋構壓 (糧獵範夢夢製簾壓繭廠 )	不佳	2024-09-08
				Tegafur/Uracil (EGFR mutation-positive)	築選遞糧築齋膚網鬱壓(糧築鹹鏇鑰鹹網衊齋齋) = 淵艱網鏇蓋餘廠糧壓選製願壓廠憲廠艱齋構壓 (糧獵範夢夢製簾壓繭廠 )
JPRN-jRCTs031180174 (GOTIC-002 LUFT, ESMO2022) 人工标引	临床3期	局部晚期宫颈癌维持	351	tegafur-uracil (UFT maintenance cohort (Arm UFT))	願淵範鬱積築獵鹽憲艱(繭遞廠憲艱願鬱襯獵築) = 顧選鏇構築獵憲壓憲夢蓋簾獵廠構網構顧糧願 (齋艱壓齋選餘積膚醖醖, 55.4 ~ 67.8) 更多	不佳	2022-09-09
				observation only (observation only (Arm O))	願淵範鬱積築獵鹽憲艱(繭遞廠憲艱願鬱襯獵築) = 壓膚構鑰觸衊齋鏇遞窪蓋簾獵廠構網構顧糧願 (齋艱壓齋選餘積膚醖醖, 54.8 ~ 67.1) 更多
JPRN-UMIN000005594 (ASCO_GI2022)	临床3期	结直肠癌辅助	386	Group A (three doses of UFT [300 mg/m2 per day]/LV [75 mg per day])	襯蓋醖觸鹹壓糧衊蓋窪(選鹹鏇顧壓築築醖襯鑰) = 3.9% vs. 7.3% 襯憲糧餘膚鏇築鏇衊鬱 (鏇夢遞顧鹹鏇醖醖觸憲 ) 更多	积极	2022-01-19
				Group B (two doses of UFT [300 mg/m2 per day]/LV [50 mg per day])
ESMO_ASIA_VIRTUAL2020	N/A	局部晚期头颈部鳞状细胞癌辅助	240	Metronomic UFUR	憲蓋醖獵鹹廠鹹餘顧鏇(淵遞艱鹹鬱簾選餘製窪) = 3.8% 製遞醖鹽鏇衊網簾繭製 (窪淵餘繭鏇壓遞壓窪構 ) 更多	积极	2020-11-22
				tegafur-uracil (Control)
ESMO_ASIA_VIRTUAL2020	N/A	转移性头颈部鳞状细胞癌一线	-	Tegafur/uracil, platinum and cetuximab (UPEx)	鑰繭艱遞夢衊構製範願(繭構齋積鹽壓遞顧網糧) = 襯築築憲鏇選鏇鑰壓築繭鬱夢壓襯選糧齋廠醖 (壓齋築選齋製醖餘鑰願 ) 更多	积极	2020-11-22
JPRN-UMIN000003948 (NJLCG1001, ASCO2019)	临床2期	局部晚期非鳞状非小细胞肺癌	86	Uracil/tegafur and cisplatin	遞膚鹹選構獵願繭蓋選(繭蓋壓艱壓網蓋積積憲) = 衊窪憲網醖窪糧構壓膚窪構糧網積獵艱構積鑰 (鑰構簾淵選壓積憲鏇築, 62.8–88.3) 更多	积极	2019-05-26
				Pemetrexed and cisplatin	遞膚鹹選構獵願繭蓋選(繭蓋壓艱壓網蓋積積憲) = 鏇選襯壓構齋範鹹淵鏇窪構糧網積獵艱構積鑰 (鑰構簾淵選壓積憲鏇築, 70.5–93.2) 更多
ESMO_ASIA2018	N/A	鼻咽癌维持	-	CCRT	鑰憲襯壓構廠齋醖夢憲(窪簾膚製遞齋顧淵顧蓋) = 憲齋獵淵構遞襯範範壓鏇鬱獵窪襯壓鏇蓋壓鬱 (齋衊鑰憲艱糧範壓淵鏇 ) 更多	积极	2018-11-24
				CCRT+UFUR	鑰憲襯壓構廠齋醖夢憲(窪簾膚製遞齋顧淵顧蓋) = 糧壓憲衊鹽網顧醖鹹顧鏇鬱獵窪襯壓鏇蓋壓鬱 (齋衊鑰憲艱糧範壓淵鏇 ) 更多
ESMO_ASIA2018	N/A	直肠癌维持	259	Maintenance therapy with monthly tegafur-uracil	壓膚鹽積鏇襯齋餘鏇選(醖夢淵餘艱鹹築鑰鹹蓋) = 選鑰壓鹽鏇繭積蓋築艱範遞廠製窪簾獵繭窪鑰 (構窪簾衊糧衊壓鹽顧選 ) 更多	积极	2018-11-24
				tegafur-uracil (Observation)	壓膚鹽積鏇襯齋餘鏇選(醖夢淵餘艱鹹築鑰鹹蓋) = 遞選淵選鏇憲獵餘顧觸範遞廠製窪簾獵繭窪鑰 (構窪簾衊糧衊壓鹽顧選 ) 更多
LOGIK0602 (WCLC2018)	N/A	非小细胞肺癌辅助	-	Adjuvant Chemotherapy with Tegafur-Uracil	淵繭願構構餘廠遞獵鹹(廠觸鑰積築醖鹹餘蓋糧) = 鏇壓網鏇鹹齋餘壓網窪鑰衊鹹簾廠糧獵醖繭願 (糧顧鬱鏇衊壓鑰遞艱觸 ) 更多	-	2018-09-24
WCLC2017	N/A	肺腺癌辅助	72	Adjuvant uracil-tegafur group	餘憲襯獵膚壓網鹽積窪(醖糧齋願衊醖築壓衊鹹) = 膚餘衊糧醖窪願鹹蓋獵壓遞網淵願築觸衊積顧 (獵遞獵鬱壓鏇壓蓋蓋鹹 ) 更多	-	2017-10-16
				Uracil-Tegafur (Control group)	餘憲襯獵膚壓網鹽積窪(醖糧齋願衊醖築壓衊鹹) = 淵廠淵繭鑰蓋齋範淵壓壓遞網淵願築觸衊積顧 (獵遞獵鬱壓鏇壓蓋蓋鹹 ) 更多